1. Cardiovascular Disease and the Patient with Diabetes and Metabolic Syndrome Nathan D. Wong, PhD, FACC, FAHA Professor and Director Heart Disease Prevention Program Division…

1. Is HRT a Replacement medication? byManuel Neves-e-Castro, MD(Lisbon, Portugal)10 th World Congress on the MenopauseJune 2002Berlin 2. HormoneHRT = ReplacementTherapy 3.…

1. P.C.R. Ernest Spitzer Cano R1 de Cardiología - HUMS 16-01-09 2. Inflamación Aterogénesis Vulnerabilidad de la Placa (1990’s) Marcadores proteicos Aterosclerosis en…

1. Numerus Clausus: traitement inefficace et suppression sans effet ? Guy-André Pelouze Chirurgien des Hôpitaux` Colloque de la MTRL Lyon le 5 octobre 2013 Conflit d’intérêt:…

1. ApoB‐Lipoprotein profile modelling to derive cardiovascular risk markers Albert de Graaf 2. Dietary fat absorptionFrom: Keith Frayn, “Metabolic Regulation - A Human…

1. PADPAD A Call to ActionA Call to Action 2. PAD: A Call to ActionPAD: A Call to Action -- What is peripheral arterial diseaseWhat is peripheral arterial disease (PAD)?…

1. Genome-wide Association StudiesEPI 519 3 November 2009Joshua C. Bis, PhDUniversity of Washington, The Type 1 Diabetes Genetics Consortium. Nature Genetics, 2009 May 10…

1. Papel de las Lipoproteínas en Aterosclerosis 2. Papel de la LDL en AterosclerosisLas LDL ingresan a la pared arterial donde son modificadasLumen del Vaso LDL…

JOURNAL CLUB JOURNAL CLUB DR.PRAVEEN NAGULA 1 Update on the evidence for PCSK9 inhibition to lower LDL cholesterol NEJM,2014 May 8 ;370:1811. 2 Background For patients who…

Terapeuticas hormonais são ou não Preventivas de DCV da mulher? Manuel Neves-e-Castro (Sociedade Portuguesa de Menopausa) Janeiro 2002 After all ... “Only 20% of women…